- Home
- VOYA vs PRAX Comparison
VOYA vs PRAX Comparison
Compare VOYA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOYA | PRAX |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.8B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VOYA | PRAX |
|---|---|---|
| Price | $75.94 | $311.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $85.09 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 741.9K | 600.5K |
| Earning Date | 02-03-2026 | 02-27-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.82 | N/A |
| Revenue | ★ $8,088,000,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.49 | $14,827.76 |
| P/E Ratio | $13.17 | ★ N/A |
| Revenue Growth | 2.91 | ★ 364.98 |
| 52 Week Low | $52.43 | $26.70 |
| 52 Week High | $79.99 | $326.91 |
Technical Indicators
Market Signals| Indicator | VOYA | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 61.64 |
| Support Level | $72.72 | $266.93 |
| Resistance Level | $77.00 | $326.83 |
| Average True Range (ATR) | 1.87 | 19.27 |
| MACD | -0.37 | -0.73 |
| Stochastic Oscillator | 42.85 | 74.67 |
Price Performance
Historical ComparisonAbout VOYA Voya Financial Inc.
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.